About A0009K0

Founded: 2018
Employees: n/a
CEO: Nam-Gu Her
WebsiteView website: www.aimedbio.com

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea.

Recent A0009K0 News & Updates

New Risk • May 24

New minor risk - Earnings quality

The company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.

Recent updates

No updates

Aimed Bio Inc. Stock Price

A0009K0 Share Price Performance

A0009K0 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Aimed Bio Inc. Key Details

About A0009K0

Recent A0009K0 News & Updates

Now 21% overvalued

Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) Earnings

New minor risk - Earnings quality

Recent updates

Aimed Bio Inc. Competitors

Samsung BiologicsLtd